Erratum: Integrating new discoveries into the “vicious cycle” paradigm of prostate to bone metastases [Cancer and Metastasis Reviews, 33, (2014), 511–525, DOI 10.1007/s10555-014-9494-4];Integrating new discoveries into the "vicious cycle" paradigm of prostate to bone metastases

Cancer and Metastasis Reviews

Volumn 33, Issue 2-3, 2014, Pages 511-525

  Cook, Leah M ^a   Shay, Gemma ^a   Aruajo, Arturo ^a   Lynch, Conor C ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Bone metastasis; Immune cells; Mathematical modeling; Prostate cancer; Stem cells; Vicious cycle

Indexed keywords

ABCIXIMAB; ALKALINE PHOSPHATASE BONE ISOENZYME; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CABOZANTINIB; COLLAGENASE 3; CYTOKINE; GEMCITABINE; INTERSTITIAL COLLAGENASE; NOX A 12; OSTEOCALCIN; PLATELET DERIVED GROWTH FACTOR; PLERIXAFOR; RETINOIC ACID; ROMIPLOSTIM; SOMATOMEDIN; STROMAL CELL DERIVED FACTOR 1; STROMELYSIN; THROMBOPOIETIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN; WY 14642; [[[3 [4 (AMINOIMINOMETHYL)PHENYL] 4,5 DIHYDRO 5 ISOXAZOLYL]ACETYL]AMINO] N [(3 METHYLPHENYL)SULFONYL]ALANINE;

ADIPOCYTE; ADRENERGIC SYSTEM; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; CANCER GROWTH; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; DENDRITIC CELL; EPITHELIAL MESENCHYMAL TRANSITION; EXOSOME; FIBROBLAST; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOREGULATION; INNERVATION; MACROPHAGE; MEGAKARYOCYTE; MESENCHYMAL STEM CELL; MESENCHYMAL STROMA CELL; METASTASIS POTENTIAL; NERVE CELL; NONHUMAN; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; STEM CELL NICHE; SUPPRESSOR CELL; THROMBOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; ADAPTIVE IMMUNITY; ANIMAL; BIOLOGICAL MODEL; BONE TUMOR; CANCER STEM CELL; COMPLICATION; INNATE IMMUNITY; MALE; METABOLISM; PAIN; PATHOLOGY; PROSTATIC NEOPLASMS; SECONDARY;

ADAPTIVE IMMUNITY; ANIMALS; BONE NEOPLASMS; HUMANS; IMMUNITY, INNATE; MALE; MODELS, BIOLOGICAL; NEOPLASTIC STEM CELLS; PAIN; PROSTATIC NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84905090183     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-014-9507-3     Document Type: Erratum

References (143)

1. Keller, E. T., & Brown, J. (2004). Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. Journal of Cellular Biochemistry, 91(4), 718-729.
2. Fizazi, K., et al. (2011). Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet, 377(9768), 813-822.
3. Choudhury, A. D., & Kantoff, P. W. (2012). New agents in metastatic prostate cancer. Journal of the National Comprehensive Cancer Network, 10(11), 1403-1409.
4. Anonymous. (2013). FDA approves radiopharmaceutical for metastatic prostate cancer. Cancer Discovery, 3(7), OF1.
5. Paget, S. (1989). The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Reviews, 8(2), 98-101.
6. Lu, X., et al. (2011). VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors. Cancer Cell, 20(6), 701-714.
7. Kang, Y., et al. (2003). A multigenic program mediating breast cancer metastasis to bone. Cancer Cell, 3(6), 537-549. (Pubitemid 36808649)
8. Sun, Y. X., et al. (2005). Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, 20(2), 318-329.
9. Kaplan, R. N., Psaila, B., & Lyden, D. (2006). Bone marrow cells in the 'pre-metastatic niche': within bone and beyond. Cancer Metastasis Reviews, 25(4), 521-529. (Pubitemid 46071861)
10. Kaplan, R. N., et al. (2005). VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature, 438(7069), 820-827. (Pubitemid 41753060)
11. Kaplan, R. N., Psaila, B., & Lyden, D. (2007). Niche-to-niche migration of bone-marrow-derived cells. Trends in Molecular Medicine, 13(2), 72-81. (Pubitemid 46201791)
12. Janowska-Wieczorek, A., et al. (2005). Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. International Journal of Cancer, 113(5), 752-760. (Pubitemid 40101256)
13. Peinado, H., et al. (2012). Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nature Medicine, 18(6), 883-891.
14. Pan, B. T., et al. (1985). Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes. The Journal of Cell Biology, 101(3), 942-948.
15. Couzin, J. (2005). Cell biology: the ins and outs of exosomes. Science, 308(5730), 1862-1863.
16. Johnstone, R. M., et al. (1987). Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). Journal of Biological Chemistry, 262(19), 9412-9420.
17. Thery, C., Zitvogel, L., & Amigorena, S. (2002). Exosomes: composition, biogenesis and function. Nature Reviews Immunology, 2(8), 569-579. (Pubitemid 37328732)
18. Schara, K., et al. (2009). Mechanisms for the formation of membranous nanostructures in cell-to-cell communication. Cellular & Molecular Biology Letters, 14(4), 636-656.
19. Ostrowski, M., et al. (2010). Rab27a and Rab27b control different steps of the exosome secretion pathway. Nature Cell Biology, 12(1), 19-30. sup pp 1-13.
20. Knudsen, B. S., & Edlund, M. (2004). Prostate cancer and the met hepatocyte growth factor receptor. Advances in Cancer Research, 91, 31-67.
21. Di Vizio, D., et al. (2012). Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease. American Journal of Pathology, 181(5), 1573-1584.
22. Webber, J., et al. (2010). Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Research, 70(23), 9621-9630.
23. Itoh, T., et al. (2012). Microvesicles released from hormone-refractory prostate cancer cells facilitate mouse pre-osteoblast differentiation. Journal of Molecular Histology, 43(5), 509-515.
24. Lee, R. J., et al. (2013). A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 19(11), 3088-3094.
25. Zhang, G., et al. (2012). A delivery systemtargeting bone formation surfaces to facilitate RNAi-based anabolic therapy. Nature Medicine, 18(2), 307-314.
26. Chen, Q., & Massague, J. (2012). Molecular pathways: VCAM-1 as a potential therapeutic target in metastasis. Clinical Cancer Research, 18(20), 5520-5525.
27. Chen, Q., Zhang, X. H., & Massague, J. (2011). Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell, 20(4), 538-549.
28. Spain, L. M., & Mulligan, R. C. (1992). Purification and characterization of retrovirally transduced hematopoietic stem cells. Proceedings of the National Academy of Sciences of the United States of America, 89(9), 3790-3794.
29. Matsuzaki, Y., et al. (2004). Unexpectedly efficient homing capacity of purified murine hematopoietic stem cells. Immunity, 20(1), 87-93. (Pubitemid 38134296)
30. Levesque, J. P., Helwani, F. M., & Winkler, I. G. (2010). The endosteal 'osteoblastic' niche and its role in hematopoietic stem cell homing and mobilization. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, UK, 24(12), 1979-1992.
31. Heissig, B., et al. (2002). Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell, 109(5), 625-637. (Pubitemid 34628725)
32. Wang, Q., et al. (2013). SUMO-specific protease 1 promotes prostate cancer progression and metastasis. Oncogene, 32(19), 2493-2498.
33. Taichman, R. S., et al. (2002). Use of the stromal cell-derived factor- 1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Research, 62(6), 1832-1837. (Pubitemid 34408510)
34. Yu, C., et al. (2012). Prostate cancer and parasitism of the bone hematopoietic stem cell niche. Critical Reviews in Eukaryotic Gene Expression, 22(2), 131-148.
35. Shiozawa, Y., et al. (2011). Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bonemarrow. Journal of Clinical Investigation, 121(4), 1298-1312.
36. Joseph, J., et al. (2012). Disseminated prostate cancer cells can instruct hematopoietic stem and progenitor cells to regulate bone phenotype. Molecular Cancer Research, 10(3), 282-292.
37. Kim, S. W., et al. (2011). Consistent interactions between tumor cell IL-6 and macrophage TNF-alpha enhance the growth of human prostate cancer cells in the bone of nude mouse. International Immunopharmacology, 11(7), 862-872.
38. Rojas, A., et al. (2011). IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR. Oncogene, 30(20), 2345-2355.
39. Pusic, I., & DiPersio, J. F. (2010). Update on clinical experience with AMD3100, an SDF-1/CXCL12-CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells. Current Opinion in Hematology, 17(4), 319-326.
40. de Nigris, F., et al. (2012). CXCR4 inhibitors: tumor vasculature and therapeutic challenges. Recent Patents on Anti-Cancer Drug Discovery, 7(3), 251-264.
41. Peng, Y., et al. (2012). Peroxisome proliferator-activated receptor alpha plays an important role in the expression of monocyte chemoattractant protein-1 and neointimal hyperplasia after vascular injury. PPAR Research, 2012, 970525.
42. Li, T., & Wu, Y. (2011). Paracrine molecules of mesenchymal stem cells for hematopoietic stem cell niche. Bone Marrow Research, 2011, 353878.
43. Pittenger, M. F., et al. (1999). Multilineage potential of adult human mesenchymal stem cells. Science, 284(5411), 143-147. (Pubitemid 29282067)
44. Karnoub, A. E., et al. (2007). Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature, 449(7162), 557-563. (Pubitemid 47525152)
45. El-Haibi, C. P., et al. (2012). Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy. Proc Natl Acad Sci U S A, 109(43), 17460-17465.
46. Jung, Y., et al. (2013). Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. Nature Communications, 4, 1795.
47. Spaeth, E. L., et al. (2013) Mesenchymal CD44 expression contributes to the acquisition of an activated fibroblast phenotype via TWIST activation in the tumor microenvironment. Cancer Research, 73, 5347-5359.
48. Yuen, H. F., et al. (2008). TWIST modulates prostate cancer cell-mediated bone cell activity and is upregulated by osteogenic induction. Carcinogenesis, 29(8), 1509-1518.
49. Lee, T. K., et al. (2006). Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clinical Cancer Research, 12(18), 5369-5376. (Pubitemid 44497250)
50. Otsu, K., et al. (2009). Concentration-dependent inhibition of angiogenesis bymesenchymal stem cells. Blood, 113(18), 4197-4205.
51. Wang, M., et al. (2007). STAT3 mediates bone marrow mesenchymal stem cell VEGF production. Journal of Molecular and Cellular Cardiology, 42(6), 1009-1015. (Pubitemid 46829204)
52. Liu, Y., et al. (2012). Intracellular VEGF regulates the balance between osteoblast and adipocyte differentiation. Journal of Clinical Investigation, 122(9), 3101-3113.
53. Okuyama, H., et al. (2006). Expression of vascular endothelial growth factor receptor 1 in bone marrow-derived mesenchymal cells is dependent on hypoxia-inducible factor 1. Journal of Biological Chemistry, 281(22), 15554-15563. (Pubitemid 43855148)
54. Qiao, L., et al. (2008). Dkk-1 secreted by mesenchymal stem cells inhibits growth of breast cancer cells via depression of Wnt signalling. Cancer Letters, 269(1), 67-77.
55. Thudi, N. K., et al. (2011). Dickkopf-1 (DKK-1) stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastases. Prostate, 71(6), 615-625.
56. Bianco, P., et al. (2013). The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. Nature Medicine, 19(1), 35-42.
57. Zheng, D., et al. (2013). Role of WNT7B-induced noncanonical pathway in advanced prostate cancer. Molecular Cancer Research, 11(5), 482-493.
58. Hoda, M. R., et al. (2012). The adipocyte-derived hormone leptin has proliferative actions on androgen-resistant prostate cancer cells linking obesity to advanced stages of prostate cancer. Journal of Oncology, 2012, 280386.
59. Liu, Y., et al. (2013). Novel adipokines and bone metabolism. International Journal of Endocrinology, 2013, 895045.
60. Sennino, B., et al. (2013). Inhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic mice. Cancer Research, 73(12), 3692-3703.
61. Sennino, B., et al. (2012). Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discovery, 2(3), 270-287.
62. Lee, R. J., & Smith, M. R. (2013). Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer. Cancer Journal, 19(1), 90-98.
63. Chanda, D., et al. (2009). Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in prostate cancer bone metastasis. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 15(23), 7175-7185.
64. Kusmartsev, S., et al. (2004). Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. Journal of Immunology, 172(2), 989-999. (Pubitemid 38113758)
65. Ueha, S., Shand, F. H., & Matsushima, K. (2011). Myeloid cell population dynamics in healthy and tumor-bearing mice. International Immunopharmacology, 11(7), 783-788.
66. Lechner, M. G., Liebertz, D. J., & Epstein, A. L. (2010). Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. Journal of Immunology, 185(4), 2273-2284.
67. Melani, C., et al. (2003). Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood, 102(6), 2138-2145. (Pubitemid 37122391)
68. Yang, L., Edwards, C. M., & Mundy, G. R. (2010). Gr-1+CD11b+ myeloid-derived suppressor cells: formidable partners in tumor metastasis. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, 25(8), 1701-1706.
69. Yang, L., et al. (2004). Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell, 6(4), 409-421. (Pubitemid 39361441)
70. Sawant, A., et al. (2013). Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer. Cancer Research, 73(2), 672-682.
71. Zhuang, J., et al. (2012). Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells. PLoS One, 7(11), e48871.
72. Danilin, S., et al. (2012). Myeloid-derived suppressor cells expand during breast cancer progression and promote tumor-induced bone destruction. Oncoimmunology, 1(9), 1484-1494.
73. Pang, Y., et al. (2013). TGF-beta signaling in myeloid cells is required for tumor metastasis. Cancer Discovery, 3(8), 936-951.
74. Nefedova, Y., et al. (2007). Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Research, 67(22), 11021-11028. (Pubitemid 350145932)
75. Fujita, M., et al. (2011). COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Research, 71(7), 2664-2674.
76. Suzuki, E., et al. (2005). Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clinical Cancer Research, 11(18), 6713-6721. (Pubitemid 41339014)
77. Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012). Coordinated regulation of myeloid cells by tumours. Nature Reviews Immunology, 12(4), 253-268.
78. Iclozan, C., et al. (2013). Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunology, Immunotherapy : CII, 62(5), 909-918.
79. Qian, B. Z., & Pollard, J. W. (2012). New tricks for metastasis-associated macrophages. Breast Cancer Research, 14(4), 316.
80. Joyce, J. A., & Pollard, J. W. (2009). Microenvironmental regulation of metastasis. Nature Reviews Cancer, 9(4), 239-252.
81. Glofcheskie, B. D., & Surgeoner, G. A. (1990). Muscovy ducks as an adjunct for the control of the house fly (Diptera: Muscidae). Journal of Economic Entomology, 83(3), 788-791.
82. Dirkx, A. E., et al. (2006). Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. Journal of Leukocyte Biology, 80(6), 1183-1196. (Pubitemid 44904956)
83. Alexander, K. A., et al. (2011). Osteal macrophages promote in vivo intramembranous bone healing in a mouse tibial injury model. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, 26(7), 1517-1532.
84. Mizutani, K., et al. (2009). The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment. Neoplasia, 11(11), 1235-1242.
85. Herroon, M. K., et al. (2013). Macrophage cathepsin K promotes prostate tumor progression in bone. Oncogene, 32(12), 1580-1593.
86. Lin, T. H., et al. (2013). CCL2 increases alphavbeta3 integrin expression and subsequently promotes prostate cancer migration. Biochimica et Biophysica Acta, 1830(10), 4917-4927.
87. Loberg, R. D., et al. (2007). Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Research, 67(19), 9417-9424. (Pubitemid 47535932)
88. Loberg, R. D., et al. (2007). CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia, 9(7), 556-562. (Pubitemid 47121829)
89. Hagemann, T., et al. (2008). "Re-educating" tumor-associated macrophages by targeting NF-kappaB. Journal of Experimental Medicine, 205(6), 1261-1268.
90. Rolny, C., et al. (2011). HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell, 19(1), 31-44.
91. Na, Y. R., et al. (2013). Cyclooxygenase-2 inhibition blocks M2 macrophage differentiation and suppresses metastasis in murine breast cancer model. PLoS One, 8(5), e63451.
92. Veltman, J. D., et al. (2010). Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma. British Journal of Cancer, 103(5), 629-641.
93. Coscia, M., et al. (2010). Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. Journal of Cellular and Molecular Medicine, 14(12), 2803-2815.
94. Di Lorenzo, G., Buonerba, C., & Kantoff, P. W. (2011). Immunotherapy for the treatment of prostate cancer. Nature Reviews. Clinical Oncology, 8(9), 551-561.
95. Djaafar, S., et al. (2010). Inhibition of T cell-dependent and RANKL-dependent osteoclastogenic processes associated with high levels of bone mass in interleukin-15 receptor-deficient mice. Arthritis and Rheumatism, 62(11), 3300-3310.
96. Sawant, A., et al. (2012). Depletion of plasmacytoid dendritic cells inhibits tumor growth and prevents bone metastasis of breast cancer cells. Journal of Immunology, 189(9), 4258-4265.
97. Zou, W., et al. (2001). Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nature Medicine, 7(12), 1339-1346.
98. Masopust, D., & Schenkel, J. M. (2013). The integration of T cell migration, differentiation and function. Nature Reviews Immunology, 13(5), 309-320.
99. Fournier, P. G., Chirgwin, J. M., & Guise, T. A. (2006). New insights into the role of T cells in the vicious cycle of bone metastases. Curr Opin Rheumatology, 18(4), 396-404. (Pubitemid 44297286)
100. Nakashima, T., & Takayanagi, H. (2009). Osteoimmunology: crosstalk between the immune and bone systems. Journal of Clinical Immunology, 29(5), 555-567.
101. Kiesel, J. R., Buchwald, Z. S., & Aurora, R. (2009). Cross-presentation by osteoclasts induces FoxP3 in CD8+ T cells. Journal of Immunology, 182(9), 5477-5487.
102. Takayanagi, H. (2010). New immune connections in osteoclast formation. Annals of the New York Academy of Sciences, 1192, 117-123.
103. Zhang, K., et al. (2011). CD8+ T cells regulate bone tumor burden independent of osteoclast resorption. Cancer Research, 71(14), 4799-4808.
104. Bidwell, B. N., et al. (2012). Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nature Medicine, 18, 1224-1231.
105. Zhao, E., et al. (2012). Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer. Oncoimmunology, 1(2), 152-161.
106. Bidwell, B. N., et al. (2012). Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med, 18(8), 1224-1231.
107. Pappalardo, A., Thompson, K. (2013). Activated gammadelta T cells inhibit osteoclast differentiation and resorptive activity in vitro. Clinical and Experimental Immunology, 174, 281-291.
108. Dieli, F., et al. (2003). Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood, 102(6), 2310-2311. (Pubitemid 37122416)
109. DeNardo, D. G., Andreu, P., & Coussens, L. M. (2010). Interactions between lymphocytes and myeloid cells regulate pro- versus antitumor immunity. Cancer Metastasis Reviews, 29(2), 309-316.
110. Roy, L. D., et al. (2013). Arthritis augments breast cancer metastasis: role of mast cells and SCF/c-Kit signaling. Breast Cancer Research, 15(2), R32.
111. Bord, S., et al. (2004). Synthesis of osteoprotegerin and RANKL by megakaryocytes is modulated by oestrogen. British Journal of Haematology, 126(2), 244-251. (Pubitemid 38961944)
112. Kacena, M. A., Gundberg, C. M., & Horowitz, M. C. (2006). A reciprocal regulatory interaction between megakaryocytes, bone cells, and hematopoietic stem cells. Bone, 39(5), 978-984. (Pubitemid 44528390)
113. Ciovacco, W. A., et al. (2010). Immature and mature megakaryocytes enhance osteoblast proliferation and inhibit osteoclast formation. Journal of Cellular Biochemistry, 109(4), 774-781.
114. Li, X., et al. (2011). Inhibitory effects of megakaryocytic cells in prostate cancer skeletal metastasis. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, 26(1), 125-134.
115. Deutsch, V. R., & Tomer, A. (2013). Advances in megakaryocytopoiesis and thrombopoiesis: from bench to bedside. British Journal of Haematology, 161(6), 778-793.
116. Gay, L. J., & Felding-Habermann, B. (2011). Contribution of platelets to tumour metastasis. Nature Reviews Cancer, 11(2), 123-134.
117. Erpenbeck, L., & Schon, M. P. (2010). Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. Blood, 115(17), 3427-3436.
118. Karpatkin, S., et al. (1988). Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. The Journal of Clinical Investigation, 81(4), 1012-1019.
119. Bakewell, S. J., et al. (2003). Platelet and osteoclast beta3 integrins are critical for bone metastasis. Proceedings of the National Academy of Sciences of the United States of America, 100(24), 14205-14210. (Pubitemid 37499215)
120. Sottnik, J. L., et al. (2013). Integrin alpha2beta 1 (alpha2beta1) promotes prostate cancer skeletal metastasis. Clinical and Experimental Metastasis, 30(5), 569-578.
121. Gupta, A., Cao, W., & Chellaiah, M. A. (2012). Integrin alphavbeta3 and CD44 pathways in metastatic prostate cancer cells support osteoclastogenesis via a Runx2/Smad 5/receptor activator of NF-kappaB ligand signaling axis. Molecular Cancer, 11, 66.
122. King, T. E., et al. (2008). The role of alpha 6 integrin in prostate cancer migration and bone pain in a novel xenograft model. PLoS One, 3(10), e3535.
123. Kerr, B. A., et al. (2013) Platelets govern pre-metastatic tumor communication to bone. Oncogene, 32, 4319-4324.
124. Mantyh, P. W., et al. (2002). Molecular mechanisms of cancer pain. Nature Reviews Cancer, 2(3), 201-209. (Pubitemid 37328789)
125. Elefteriou, F. (2008). Regulation of bone remodeling by the central and peripheral nervous system. Archives of Biochemistry and Biophysics, 473(2), 231-236.
126. Yoneda, T., et al. (2011). Involvement of acidic microenvironment in the pathophysiology of cancer-associated bone pain. Bone, 48(1), 100-105.
127. Magnon, C., et al. (2013). Autonomic nerve development contributes to prostate cancer progression. Science, 341(6142), 1236361.
128. Mistry, T., et al. (2007). Obesity and prostate cancer: a role for adipokines. European Urology, 52(1), 46-53. (Pubitemid 46803036)
129. Campbell, J. P., et al. (2012). Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice. PLoS Biology, 10(7), e1001363.
130. Kondo, H., Takeuchi, S., & Togari, A. (2013). beta-Adrenergic signaling stimulates osteoclastogenesis via reactive oxygen species. American Journal of Physiology, Endocrinology and Metabolism, 304(5), E507-E515.
131. Hassan, S., et al. (2013). Behavioral stress accelerates prostate cancer development in mice. The Journal of Clinical Investigation, 123(2), 874-886.
132. Grytli, H. H., et al. (2013). Use of beta-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy. Prostate, 73(3), 250-260.
133. Macklin, P., & Lowengrub, J. (2007). Nonlinear simulation of the effect of microenvironment on tumor growth. Journal of Theoretical Biology, 245(4), 677-704.
134. Nagl, S. (2005). Cancer bioinformatics: from therapy design to treatment. Chichester: Wiley.
135. Wodarz, D., & Komarova, N. L. (2008). Computational biology of cancer: lecture notes and mathematical modeling. Hackensack: World Scientific.
136. Macal, C. M., & North, M. J. (2010). Tutorial on agent-based modelling and simulation. Journal of Simulation, 4(3), 151-162.
137. Wolfram, S. (2002). A new kind of science. Champaign: Wolfram Media.
138. Ribba, B., et al. (2004). The use of hybrid cellular automaton models for improving cancer therapy. Lecture Notes in Computer Science, 3305, 444-53. (Pubitemid 39742858)
139. Anderson, A. R. A., Chaplain, M. A. J., & Rejniak, K. A. (2007). Single-cell-based models in biology and medicine. Basel: Birkhäuser.
140. Basanta, D., et al. (2009). The role of transforming growth factor-beta-mediated tumor-stroma interactions in prostate cancer progression: an integrative approach. Cancer Research, 69(17), 7111-7120.
141. Pivonka, P., & Komarova, S. V. (2010). Mathematical modeling in bone biology: from intracellular signaling to tissue mechanics. Bone, 47(2), 181-189.
142. Ryser, M. D., Nigam, N., & Komarova, S. V. (2009). Mathematical modeling of spatio-temporal dynamics of a single bone multicellular unit. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, 24(5), 860-870.
143. Ryser, M. D., Qu, Y., & Komarova, S. V. (2012). Osteoprotegerin in bone metastases: mathematical solution to the puzzle. PLoS Computational Biology, 8(10), e1002703.